Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 10, Pages 2471
Publisher
MDPI AG
Online
2022-10-08
DOI
10.3390/biomedicines10102471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)
- (2022) Juan Xia et al. BIOMEDICINE & PHARMACOTHERAPY
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- (2022) Paul A. Heidenreich et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica
- (2022) J.R. González-Juanatey et al. REVISTA CLINICA ESPANOLA
- Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
- (2022) Hayah Kassis-George et al. Therapeutics and Clinical Risk Management
- Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA ( VerICiguaT Global Study in Subjects with HFrEF ) Trial
- (2021) Adriaan A. Voors et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
- (2021) Alberto Aimo et al. HEART FAILURE REVIEWS
- Vericiguat for Heart Failure with Reduced Ejection Fraction
- (2021) Carlo Mario Lombardi et al. Current Cardiology Reports
- Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial
- (2020) Javed Butler et al. CIRCULATION
- Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
- (2020) Michael Boettcher et al. CLINICAL PHARMACOKINETICS
- Vericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure
- (2020) John C. Burnett NEW ENGLAND JOURNAL OF MEDICINE
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- (2020) Paul W. Armstrong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of heart failure
- (2020) Amy Groenewegen et al. EUROPEAN JOURNAL OF HEART FAILURE
- Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis
- (2020) Alberto Aimo et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction
- (2020) Paul W. Armstrong et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
- (2020) Michele Emdin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial
- (2019) Burkert Pieske et al. EUROPEAN JOURNAL OF HEART FAILURE
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator
- (2018) Paul W. Armstrong et al. JACC-Heart Failure
- Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
- (2018) Hélène Nougué et al. EUROPEAN JOURNAL OF HEART FAILURE
- Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
- (2017) Burkert Pieske et al. EUROPEAN HEART JOURNAL
- Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study
- (2017) Gerasimos Filippatos et al. EUROPEAN JOURNAL OF HEART FAILURE
- New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations
- (2017) Elles M. Screever et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction
- (2015) Mihai Gheorghiade et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)
- (2014) Burkert Pieske et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- (2013) Clyde W. Yancy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
- (2013) Stephen J. Greene et al. Journal of the American Heart Association
- Soluble guanylate cyclase: a potential therapeutic target for heart failure
- (2012) Mihai Gheorghiade et al. HEART FAILURE REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More